



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

SEP 25 2001

RECEIVED

Application of:

Norman Nashed

Examiner: S. Qazi

Serial No.: 09/619,493

Group Art Unit: 1616

Filed: July 19, 2000

Title: THERAPEUTIC GESTAGENS FOR THE TREATMENT OF PREMENSTRUAL
DYSPHORIC DISORDER

REPLY

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the office action dated August 21, 2001, the following remarks are
provided for consideration:

REMARKS

In response to the "restriction requirement" in the above-referenced application,
applicants elect, with traverse, Group V (claims 3-8, 12, 13, 15-17 and 19-23), drawn to a
method of treating PMDD comprising administering a gestagen, drospirenone, and an estrogen,
ethinylestradiol.

It is noted that the "restriction requirement" is, in effect, a combination of a) a restriction
requirement between a method comprising the administration of a gestagen alone, and a method
comprising the administration of a gestagen and an estrogen; and b) a requirement to elect a
species from the genus of gestagens and a species from the genus of estrogens. Compare, e.g., the